Phil Skolnick

Years Active: 2019-2024
Publications (10 Years): 5

Opiant Pharmaceuticals

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Opiant Pharmaceuticals

United States

Chief Scientific Officer

National Institutes of Health Jan 10 2010 - Feb 05 2017

United States

Director, Div. Therapeutics & Medical Consequences :: National Institute on Drug Abuse

DOV Pharmaceutical, Inc.

United States

Chief Scientific Officer

Eli Lilly and Company

United States

Lilly Research Fellow :: Neuroscience

National Institutes of Health

United States

Chief :: Laboratory of Neuroscience

Publications

Mark Ellison, Emily Hutton, Lynn Webster, Phil Skolnick
Reversal of Opioid-Induced Respiratory Depression in Healthy Volunteers: Comparison of Intranasal Nalmefene and Intranasal Naloxone. Journal of clinical pharmacology (2024)
Mark Ellison, Emily Hutton, Lynn Webster, Phil Skolnick
Reversal of Opioid-Induced Respiratory Depression in Healthy Volunteers: Comparison of Intranasal Nalmefene and Intranasal Naloxone. Journal of clinical pharmacology 64 (7) (2024)
Mark Ellison, Emily Hutton, Lynn Webster, Phil Skolnick
Reversal of Opioid-Induced Respiratory Depression in Healthy Volunteers: Comparison of Intranasal Nalmefene and Intranasal Naloxone. Journal of clinical pharmacology 64 (7) (2024)
Phil Skolnick, Roger Crystal
Cannabinoid1 (CB-1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose. Journal of neural transmission (Vienna, Austria : 1996) 127 (2) (2019)
Philip Krieter, Shwe Gyaw, Roger Crystal, Phil Skolnick
Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. The Journal of pharmacology and experimental therapeutics 371 (2) (2019)

Phil Skolnick.css-eqlu8i{font-size:small;padding-left:4px;}